Expert Interview
Diving into the FDA's concerns of Reata Pharma' s drug Omaveloxolone, in treating Friedreich’s Ataxia
Ticker(s): RETAInstitution: Swedish Neuroscience Institute
- Movement Disorders Specialist, Dept. of Neurology, Swedish Neuroscience Institute (formerly Associate Professor, Movement Disorders, Neurology and Neurotherapeutics at UT Southwestern Medical Center.)
- Currently manages over 100 patients with Parkinson's Disease.
- Specializes in leading-edge care to treat Parkinson disease, ataxias, dystonia, Huntington’s disease and is involved in clinical trials that complement the standard of care and explore future treatments.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
